ALGNAlign Technology

$142.75+7.7% 1Y

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though cheap against its own history.

1 good, 2 neutral
What the price assumes~+6% a yearderived · Jun 30, 2026

Priced for ~6% a year FCF growth. Roughly in line with its three-year revenue growth of 3% a year.

Vs its own P/E rangecheaper than 88% of its own historyderived

Cheap vs its own history: P/E 24.9 vs a 43.5 median over 41 quarters (−43% vs median).

Vs sector (EV/EBIT)21.9×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market
FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What ALGN's price assumes

Align Technology trades at 24.9× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.

24.9

Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group

Price / sales
3.23

Price / sales · today's price, fiscal year to Dec 31, 2025

Free cash flow yield
4.9%

Free cash flow yield · Medical Instruments & Supplies median 3.4%

Growth the price implies
+6.0%

Growth the price implies · The price pays for +6.0% free cash flow growth a year for a decade; the business has delivered +1.2% a year over the last three.

Details›
Price / booktoday's price, fiscal year to Dec 31, 2025
3.22
EV / EBITtoday's price, fiscal year to Dec 31, 2025
21.9
EV / salestoday's price, fiscal year to Dec 31, 2025
2.96
Healthcare median P/E509 names
26.2
Medical Instruments & Supplies median P/E33 names
39.6
Free cash flow, trailing twelve months
$634M
Market capitalisation
$13.0B
3-year revenue growth
+3.5%
3-year free cash flow growth
+1.2%
What the market has paid for these earnings: 41 quarters of its own multiple × $5.74 of trailing earnings per share
MethodPer share
Its own P/E history, lower quartile$183.26
Its own P/E history, median$249.54
Its own P/E history, upper quartile$371.30
52-week range$124.88 – $197.51
Today$142.75

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.